Search

everythinglearnresearchcommunity

for

Search:↓

Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.

Frontal fibrosing alopecia mainly affects women over 50, causing hair loss and specific skin changes.

Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.

Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.

Frontal fibrosing alopecia is linked to four genetic areas, especially the HLA-B*07:02 allele.

Rb-bFGF improves hair transplant results and patient satisfaction with fewer complications.

Frontal fibrosing alopecia in families shows similar signs to individual cases and may have a genetic link.

The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.

Some postmenopausal women with frontal fibrosing alopecia stopped losing hair with finasteride treatment, hinting at a possible hormonal cause.

Hepatitis C treatment may cause frontal fibrosing alopecia.

BFNB could be a promising treatment for hair growth.

The GH-IGF-I axis is likely involved in the hormonal imbalances seen in non-obese women with functional hyperandrogenism.

A man with kidney tumors and lung cysts was diagnosed with Birt–Hogg–Dubé syndrome and treated successfully, with genetic testing confirming the diagnosis.

A young woman developed facial bumps before hair loss, which is unusual for her condition.

Frontal fibrosing alopecia is a challenging hair loss condition with no known cause or definitive treatment.

The mutant HR bmh protein mis-localizes in cells, affecting skin and hair development.

Frontal fibrosing alopecia can occur in children, not just postmenopausal women.

A new mutation in the FLCN gene linked to Birt-Hogg-Dube syndrome was found, suggesting people with certain lung collapse should be tested for this mutation and screened for kidney and colon cancer.

FPHL is a common, age-related, genetic hair loss with unclear causes and limited treatment options.

D-OCT shows increased blood vessel growth in response to tissue damage in Frontal Fibrosing Alopecia and is useful for diagnosis and monitoring.

Dermatologists should carefully choose treatments for FFA to avoid worsening the condition.

IFHUT shows better hair growth than FUE, but needs improvements in positioning, speed, and accuracy.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

A 60-year-old man with a long-term balding condition also developed a rare hair loss condition usually seen in postmenopausal women.

People with Birt-Hogg-Dubé syndrome often have lung problems and delayed diagnosis, and better recognition of CT scan signs could improve diagnosis and management.

FFA in young women is often missed, and no single treatment works best.

EFBL offers hidden incisions, faster recovery, and fewer risks, but may raise hairline and cost more.

A married couple both developed a rare type of hair loss, possibly due to shared environmental factors.

Early treatment and multidisciplinary care are key to managing Frontal Fibrosing Alopecia and preventing further hair loss.

Intralesional betamethasone and oral hydroxychloroquine improved hair loss in a woman with frontal fibrosing alopecia.